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Abstract: Significant progresses have been made in the last 5 years towards the ultimate goal to provide universal access 
to care for all HIV/AIDS patients needing antiretroviral treatment in resource-poor countries. However, many barriers are 
still to be overcome, including () cost of care for the individual, () stigma, () lack of qualified human resources and 
infrastructure, especially in the rural setting, () rescue drugs for failing patients and () pediatric formulations. Priority 
actions to be promoted if the fight against HIV/AIDS is to be successful include: (i) promoting access to care in the rural 
areas, (ii) strengthening of basic health infrastructures, (iii) waiving of users’ fee to get ARV, (iv) a larger variety of 
drugs, with particular regard to fixed dose combination third line drugs and pediatric formulations, (v) local quality 
training and (vi) high quality basic and translational research. While the universal access to HIV care is crucial in 
developing countries, a strong emphasis on prevention should be maintained along. 
BACKGROUND 
  Despite the remarkable successes achieved in the North 
of the world in the last decade, mainly due to the increasing 
availability of new classes of drugs, the HIV/AIDS epidemic 
is still spreading in the poor world in the South. According to 
UNAIDS, 33 million persons were living with HIV/AIDS at 
the end of 2007, 94% of whom in resource-poor countries 
[1]. The HIV prevalence rate in the adult population is higher 
in the African continent. However, the absolute number of 
persons living with HIV/AIDS is higher in the Asian 
continent, more densely populated. 
  As a general rule, the fight against any diseases is multi-
factorial and may not be restricted to only one component. 
HIV/AIDS probably represents the paradigm of disease 
requiring a wide spectrum of interventions (medical, social, 
cultural, economic, etc.) to be finally controlled and defeated. 
  Among these interventions, improving access to adequate 
medical care for those in need is crucial, as demonstrated in 
those countries where the open access to antiretroviral drugs 
has caused an unprecedented decrease in suffering and 
deaths. However, it is to be strongly reaffirmed that access to 
pharmacological care needs to go along with renewed 
preventive efforts in the population. 
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  This brief article will focus on the problems and 
constraints that represent the main barriers to the effective 
daily implementation of any project to fight HIV/AIDS in 
resource-limited settings. These problems need to be 
comprehensively taken into account if the fight against 
HIV/AIDS is to be successful. 
  While recognizing that any geographical setting may offer 
specific epidemiological and socio-cultural problems, this article 
is mainly based on our African experience, with particular regard 
to Burkina Faso (ranking 176/177 in the 2007 list of Human 
Development Index – HDI), where the University Hospital of 
Brescia and the NGO Medicus Mundi Italy cooperates with our 
African counterparts (the Camillian religious Order Vice-
Province in Burkina Faso) to fight HIV/AIDS in the country. This 
article is based on the 6-year collaborative experience in the frame 
of the ESTHER (Ensemble pour une Solidarité Thèrapeutique 
Hospitalière en Reseau) project involving 4 different health 
facilities in the suburbs of capital city Ouagadougou (St Camille 
Medical Center, Centre d’Accueil Notre Dame de Fatima - 
CANDAF, Bio-Molecular Research Center “Pietro Annigoni” - 
CERBA) and in the rural District of Nanoro (St Camille District 
Hospital). As to 31
st December 2008, our team is following an 
active cohort consisting of over 1.000 adult patients and over 100 
children under HAART. 
THE PROBLEMS ENCOUNTERED 
  As well as in the industrialized world, the problems that 
are to be addressed in the fight against HIV/AIDS are multi-
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a. Cost of Care 
  The complex system that has made the antiretroviral 
drugs cost reduction possible in the last decade even in the 
poor world will be the subject of other articles in this special 
issue and will not be reviewed by us. Cost reduction of drugs 
has been the corner-stone of a renewed interest in the fight 
against HIV/AIDS in resource-poor countries and has served 
as a locomotive for a more comprehensive approach. The 
international funding, offered until now by different agencies 
(Global Fund, World Bank, UNITAID/Clinton Foundation, 
PEPFAR, etc.), is assuring an increasingly more adequate 
coverage (at least for standard first line drugs) for those in 
need in resource-limited settings. 
  Since the early nineties, apart from leprosy and 
tuberculosis, patients in Burkina Faso are expected to pay a 
contribution to receive care as suggested by the Bamako 
Initiative strategy. Adult (but not pediatric) HIV/AIDS 
patients are also today expected to pay a 1.500 CFA/month 
fee (roughly 2,5 euros) to receive antiretroviral drugs by the 
Government. This contribution is intended to make 
sustainability of the drug procurement possible should the 
international aid be reduced in the future. However, two 
interlinked problems are arising at the peripheral level: 
1.  for how long the free procurement of antiretroviral 
drugs may be assured by the international 
community? This concern has forced a number of 
resource-poor countries to charge an out-of-pocket 
contribution to the HIV-infected persons receiving the 
drugs, as it is the case for Burkina Faso; 
2.  as a consequence, this phenomenon has already been 
described as a major factor of therapy interruptions in 
many poor settings [2]. Also in our experience, 
charging user fees to deliver antiretroviral drugs has 
resulted in loss to follow-up. Unpublished data from 
our cohort have shown that out-of-pocket contribution 
is a major barrier for as many as 20% of patients in 
the urban setting and for as many as 90% of patients 
in the rural areas! (data non published). 
  Finally, cost of care has also to take into account other 
direct and indirect costs such as transportation and loss of 
working days respectively, that may also contribute to loss to 
follow-up of HIV/AIDS patients. 
b. Qualified Human Resources 
  According to the World Health Organization (WHO), the 
number of physicians, and to a lesser extent of other health 
personnel, working in resource limited countries is 
dramatically poor. As a striking comparison, the number of 
medical doctors working in Burkina Faso (14 million people) 
is estimated to be 789 [3] a number that is roughly one eight 
of the over six thousands medical doctors registered in the 
Italian Province of Brescia (1,1 million inhabitants) where 
one of us (FC) is currently practicing. Furthermore, if 
HIV/AIDS is probably the most important public health 
challenge in such countries, many other causes of morbidity 
and mortality are to be considered (infant mortality, maternal 
mortality, malaria, diarrheal diseases, vaccine preventable 
diseases, etc.). Among the many problems arising from such 
lack of qualified health personnel, we would like to highlight 
the following: 
1.  most qualified health personnel in resource-limited 
settings are concentrated in urban areas, where 
opportunities for profit are higher, leaving rural areas, 
where the need for health care is more urgent, 
understaffed. In rural areas of Burkina Faso, 
monitoring of HIV-infected patients under HAART is 
then the responsibility of nurses, who often have to 
rely exclusively on clinical criteria for efficacy and 
toxicity monitoring. As a consequence, the most 
tolerable drugs are to be used in first line regimens in 
these settings; 
2.  the drainage of health personnel from resource-
limited settings to satisfy the health needs of 
industrialized world may be understood from an 
individual standpoint, but it is unacceptable and 
unbearable from the community standpoint in the 
long running; 
3.  training and qualification of health personnel in the 
fight against HIV/AIDS in resource-limited setting is 
often not adequate. Long overseas training may result 
in loss of human resources for the need of their 
countries and should be avoided by promoting local 
training opportunities; 
4.  vertical projects to fight HIV/AIDS are usually more 
easily funded than those projects addressing other 
diseases, leading to the paradoxical situation of 
attracting more local medical doctors or otherwise 
health personnel who are diverted from their duties in 
other equally crucial sectors. 
  We strongly believe that any technical or humanitarian 
partnership must include a strong training component. In our 
ESTHER (Ensemble pour une Solidarité Thérapeutique 
Hospitalière en Reseau) project in Burkina Faso, the 
University of Brescia and the University of Ouagadougou 
has signed an agreement where training is a crucial 
component. 
c. Infrastructure 
  Luckily, the scaling-up of antiretroviral drugs in the 
developing world was not prevented by the scarcity of 
laboratory to monitor safety and efficacy of antiretroviral 
therapy. Millions of individuals would have died before the 
goal of settling an efficient laboratory network had been 
achieved. However, the necessity of a basic infrastructure 
performing at least safety monitoring and CD4 cell count is 
dramatically needed, especially in underprivileged rural 
areas. As a consequence, CD4+-based switching to second-
line treatment in rural areas is often very late, with severe 
clinical consequences. In rural areas of Burkina Faso, access 
to health establishment with CD4+ count facilities is limited, 
especially for women and during the rainy season. The 
spreading of viral resistance to available drugs also require 
the immediate research effort to identify simplified methods 
to assess viremia and the installation of regional resistance 
monitoring institutions. In our opinion, the strengthening of 
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to improve the fight against HIV/AIDS, should be viewed as 
a broader perspective aim to contribute to the greater long 
term objective to improve health. 
d. Socio-Cultural Aspects 
  The strong impact that socio-cultural factors may play in 
both HIV detection and treatment may not be 
overemphasized in resource-limited (and even in 
industrialized) countries. We would like to highlight the 
most important socio-cultural barriers that substantially limit 
the effectiveness of any HIV control program in real life. 
1.  gender may play an important role in favoring or 
hampering access to antiretroviral drugs and 
compliance. In our experience, PMTCT (Prevention 
of Mother-to-Child Transmission) activities were 
crucial to identify HIV infected pregnant women. 
Even if VCT (Voluntary Counseling and Testing) 
uptake rate was far than optimal using an opt-in 
strategy [4], women were nonetheless favored since 
their access to care resulted to be earlier than that of 
their male partners. Females might also be more 
prone to screening wherever gender context permits 
[5]; 
2.  poor education was earlier considered an argument to 
advise against the scaling-up of antiretroviral therapy 
in resource-poor countries for fear of inadequate 
comprehension of the complex therapeutic regimens 
by patients. In our experience illiteracy was indeed a 
relative obstacle. However, careful counseling and 
appropriate communication techniques (anthropomorphic 
drawings, etc.) were able to compensate more than 
adequately a lack of education. In a recent multicenter 
study in various sub-Saharan African countries, poor 
education has also been reported to be correlated to 
exclusive breastfeeding (negative correlation) and 
prolonged breastfeeding (positive correlation) [6]. 
Registered compliance to scheduled out-patient 
departments visits with the caring teams in Burkina 
Faso were in the same range of those registered in the 
industrialized world [7]; 
3.  stigma is also a powerful obstacle to care and 
prevention of HIV/AIDS. The success rate of contact 
tracing and caring of family members of HIV-
infected pregnant women (PMTCT-plus) has been 
variable in different settings [8] mainly due to 
reticence of family members to undergo HIV testing. 
Rejection of the infected partner (particularly if 
female) may have a deleterious effect on access to 
care for her and her offspring. Again, stigma has been 
reported to have dramatic negative impact on infant 
feeding modalities, preventing the adoption of safe 
practices such as formula feeding [9]. 
  While addressing the interested readers to read more 
comprehensive treatises on the socio-cultural aspects of 
health, we only would like to advise against any HIV control 
program that does not take into preliminary consideration 
those aspects that may later result to be an insuperable 
barrier to its effective implementation. 
e. Drug-Specific Constraints 
  When considering the impressive scaling-up of 
antiretroviral drugs in developing countries in the last 5 
years, the balance is certainly positive. However, treating an 
HIV-infected patient in the south of the world is even today 
much more difficult than in western industrialized countries: 
1.  treatment guidelines: criteria to start ad change 
HAART in resource-limited settings are mainly 
clinical and/or immunological: (i) CD4 cell count 
below 200/l irrespective of clinical stage, (ii) WHO 
stage IV irrespective of CD4 cell count, (iii) WHO 
clinical stage III and CD4 cell count below 350/l 
[10]. WHO guidelines are being revised and an earlier 
initiation of HAART is being advocated to avoid the 
mortality excess observed during the first 6 month of 
therapy. Furthermore, recent data suggest that an 
earlier initiation of HAART is associated with longer 
AIDS-free period and improved survival [11]. The 
emerging and long-anticipated problem of viral 
resistance limits in real life the effectiveness 
therapeutic decisions based only on clinical (or 
immunological) grounds, even if recent reports are 
somehow reassuring [12]. Second-line drugs are 
scarce and will probably experience a short effective 
period due to the above-mentioned problem of 
resistance. Virtually no third-line regimens are 
available at the present time in resource-limited 
settings; 
2.  toxicity: (i) stavudine is still considered a suitable 
drug for first-line regimens [10], despite its well 
recognized toxicity (peripheral neuropathy), because 
of its low cost and its poor potential for mielotoxicity 
in areas or malaria endemicity; (ii) NNRTI are 
recommended for first-line regimens. However, in 
areas with high fertility rate, both nevirapine 
(hypersensitive reactions) and efavirenz (teratogenic 
potential) have disadvantages. 
3.  drug storage conditions are far from optimal in 
developing countries, requiring all effort to enhance 
their stable shelf-live conditions; 
4.  pediatric HIV infection has dramatic epidemiological 
dimensions in the south of the world. However, only 
4% of all persons under HAART in Burkina Faso are 
children [13], probably due to family reticence to 
children testing and to the exclusive urban location of 
most pediatric centers delivering antiretroviral drugs. 
Furthermore, pediatric formulations are not given 
adequate priorities in pharmaceutical research 
activities. 
f. Specific Issues 
1.  Pregnancy and lactation: (i) the use of first-line 
regimens containing NNRTI in countries with high 
fertility rates may expose to the risk of teratogenicity 
(efavirenz) or hypersensitivity reactions (nevirapine); 
(ii) the advocated earlier criteria for HAART in 
pregnancy [14] will have a favorable impact on 
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enhance the risk of viral resistance; (iii) the risk of 
perinatal transmission via  lactation requires 
innovative strategies, including HAART during the 
lactation period irrespective of maternal criteria to 
start HAART [16]. 
2.  HIV-HBV co-infection: in resource-poor countries, 
co-infection with hepatotropic viruses is highly 
prevalent. In Burkina Faso, as many as 10% of our 
HIV-infected patients are also infected with HBV 
[17], requiring that drugs that exert activity against 
both viruses (lamivudine, emtricitabine, tenofovir) are 
largely available and used [18]. 
3.  HIV-TB co-infection: 9.3 million new cases of 
tuberculosis (TB) were estimated to occur in 2007, 
1.4 million of whom in HIV-infected persons, 
resulting in 1.7 million deaths worldwide [19]. In sub-
Saharan Africa, TB is probably the first cause of 
death among HIV-infected patients [20]. HAART 
decreases the risk of tuberculosis and other 
opportunistic diseases in HIV-infected patients [21]. 
Furthermore, early HAART may increase survival in 
HIV-TB co-infected patients. However, severe 
constraints to the provision of HIV treatment in the 
context of poor TB control exist: (i) the great burden 
on undiagnosed TB at programme entry, (ii) complex 
drug-drug interactions between rifampicin and 
antiretrovirals of the NNRTI (Non Nucleosidic 
Reverse Transcriptase Inhibitor) and PI (Protease 
Inhibitor) classes and finally (iii) the risk of TB 
transmission in HIV care settings, especially at the 
light of the emergence of multi-drug and extensively-
drug resistance in M. tuberculosis. 
WHERE WE ARE AND WHAT DO WE NEED IN 
REAL LIFE? 
  In Burkina Faso and other resource-limited settings, 
many good news are to be recorded. 
  First of all, the availability of generic drugs, of 
international funding and transfer of technical assistance 
have made a quick scaling-up of HAART possible despite 
the many difficulties encountered. International and national 
guidelines have also contributed to assure quality. Secondly, 
the spectrum of available drugs has progressively widened, 
allowing the definition of standard second-line regimens. A 
few drugs are also available to treat HIV-HBV co-infection. 
The availability of thermo stable lopinavir/r and of fixed 
dose combinations have facilitated drug storage and patients’ 
compliance. The main limit of such a process, i.e. the urban 
focus of scaling-up, was probably unavoidable. In cities, in 
fact, many favoring factors were present: (i) patients’ 
concentration and patients’ associations (ii) equipped and 
staffed hospitals, (iii) adequate technologies for laboratory 
workout. 
  Despite a number of excellent achievements, a lot still 
need to be done. Starting from our experience in fighting 
HIV/AIDS in developing countries, we estimate that the 
following actions may not be delayed further if the 
Millennium Development Goal n. 6 (Combat HIV/AIDS, 
malaria and other diseases) is to be achieved. 
1.  Promoting access to HAART in rural areas is a 
priority. To do so efficiently, drugs with poor 
potential for toxicity are needed since clinical 
management is mainly relied upon nurses with 
limited access to laboratory tests. Poor tolerance may 
also cause low compliance, though increasing the 
spread of resistance. Such an extensive approach is 
financially demanding because a larger number of 
patients will require drugs and a large scale training 
of peripheral personnel will be needed. 
2.  To promote access to antiretroviral care in 
underprivileged areas, strengthening of basic health 
infrastructure to assure safety monitoring is a priority 
and may also benefit many other aspects of health 
promotion. 
3.  Users’ fees to have access to antiretroviral treatment 
in countries where yearly pro-capita health budget is 
as low as 10-15 US dollars are to be abolished. The 
international community needs to look for and find 
alternative ways to insure sustainability of drug 
procurement in the future. The loss to follow-up of 
HIV-infected persons who deliberately choose to 
give-up treatment is a dreadful risk for the individual, 
his/her family and the community where he or she 
lives. 
4.  A larger variety of drugs is needed to better tailor 
first-line and second-line regimens should first line 
drugs fail. Operational research is crucial in 
developing countries to better transfer results from 
randomized clinical trial into real life [22, 23]. 
5.  Time has come to consider third line drugs should 
failure occur in those patients with a long treatment 
history in resource-poor countries. Fixed dose 
combination drugs are eagerly awaited to save lives 
and to limit the spreading of resistant viral strains. 
6.  Pediatric HIV infection is an increasing large problem 
that may not wait further for specific solutions. 
Pediatric drug formulations are desperately needed to 
help hundreds of thousands mothers and tutors to treat 
their infants. 
7.  Viral resistance spreading is ongoing. Monitoring and 
surveillance of such phenomenon is crucial in order to 
prevent and anticipate large scale pharmacological 
failures. The introduction of new molecules in a 
specific region needs to take into account the results 
of resistance surveillance. 
8.  High quality research is to be designed and 
implemented in collaboration between researchers 
from the south and the north in order to assure that 
adequate technology platform is in line with priority 
research questions. Research activities need to be 
adequately funded and must address both basic 
questions and operational questions. Socio-cultural 
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and operational research activities that are able to 
provide clues to make antiretroviral care as 
widespread as possible are welcome. 
9.  Training in HIV/AIDS management is crucial. High 
quality training is to be performed in the field in order 
to optimize resources and to avoid purely academic 
training. Academic and research institutions of the 
south need to take responsibility for such training, 
with the constant help of the international community. 
The creation of regional training networks is of 
particular added value. Among other valuable 
initiatives, the network RAF-VIH (www.raf-vih.org) 
gather training Institutions in Benin, Burundi, 
Burkina Faso, Sénégal, Congo Democratic Republic 
and Niger with the support of many international 
Agencies and Universities. 
10.  Last, but not least, we strongly believe that effective 
care effort should never divert attention from 
preventive activities, as it has occurred too widely in 
the western society after the availability of HAART. 
  The last achievement that we would like to promote is 
Millennium Development Goal n. 8 (Develop a global 
partnership for development). The fight to provide free 
access to anti-HIV drugs and care is a component of the 
wider struggle for global development, including education, 
equity and freedom. 
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